

1 Article

## 2 Generation of a Mouse Model Lacking the Non- 3 Homologous End-Joining Factor Mri/Cyren

4 Sergio Castañeda-Zegarra <sup>1,2,5</sup>, Camilla Huse <sup>1,2,5</sup>, Øystein Røsand <sup>1,2,5</sup>, Antonio Sarno <sup>1,2</sup>, Mengtan  
5 Xing <sup>1,2</sup>, Raquel Gago-Fuentes <sup>1,2</sup>, Qindong Zhang <sup>1,2</sup>, Amin Alirezaylavasani <sup>1,2</sup>, Julia Werner <sup>1,2,3</sup>,  
6 Ping Ji <sup>1</sup>, Nina-Beate Liabakk <sup>1</sup>, Wei Wang <sup>1</sup>, Magnar Bjørås <sup>1,2</sup>, Valentyn Oksenyich <sup>1,2,4,\*</sup>

7 <sup>1</sup> Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology,  
8 7491 Trondheim, Norway; sergio.m.c.zegarra@ntnu.no (S.CZ.); camilhus@stud.ntnu.no (C.H.);  
9 oystein.rosand@ntnu.no (Ø.R.); antonio.sarno@ntnu.no (A.S.); mengtan.xing@ntnu.no (MT.X.);  
10 raquel.gago-fuentes@ntnu.no (R.GF.); qindongz@stud.ntnu.no (Q.Z.); aminalir@stud.ntnu.no (A.L.);  
11 ping.ji@ntnu.no (P.J.); nina.beate.liabakk@ntnu.no (NB.L.); wei.wang@ntnu.no (W.W.);  
12 magnar.bjoras@ntnu.no (M.B.); valentyn.oksenych@ntnu.no (V.O.)

13 <sup>2</sup> St. Olavs Hospital, Trondheim University Hospital, Clinic of Medicine, Postboks 3250 Sluppen, 7006  
14 Trondheim;

15 <sup>3</sup> Heidelberg University, Heidelberg, Germany; julia.werner@stud.uni-heidelberg.de (J.W.)

16 <sup>4</sup> Department of Biosciences and Nutrition (BioNut), Karolinska Institutet, 14183 Huddinge, Sweden (V.O.)

17 <sup>5</sup> These authors contributed equally (S.CZ.); (C.H.); (Ø.R.)

18 \* Correspondence: valentyn.oksenych@ntnu.no;

19

20 **Abstract:** Classical non-homologous end joining (NHEJ) is a molecular pathway that detects,  
21 processes and ligates DNA double-strand breaks (DSBs) throughout the cell cycle. Mutations in  
22 several NHEJ genes result in neurological abnormalities and immunodeficiency both in humans and  
23 mice. The NHEJ pathway is required for the V(D)J recombination in developing B and T lymphocytes,  
24 and for class switch recombination in mature B cells. Ku heterodimer formed by Ku70 and Ku80  
25 recognizes DSBs and facilitates recruitment of accessory factors (e.g., DNA-PKcs, Artemis, Paxx and  
26 Mri/Cyren) and downstream core factors subunits XLF, XRCC4 and Lig4. Accessory factors might be  
27 dispensable for the process depending on the genetic background and DNA lesion type. To  
28 determine the physiological role of Mri in DNA repair and development, we introduced frame-shift  
29 mutation in the Mri gene in mice. We then analyzed development of *Mri*-deficient mice as well as  
30 wild type and immunodeficient controls. Mice lacking Mri possessed reduced levels of class switch  
31 recombination in B lymphocytes and slow proliferation of neuronal progenitors when compared to  
32 wild type littermates. Human cell lines lacking Mri were as sensitive to DSBs as WT controls. Overall,  
33 we concluded that Mri/Cyren is largely dispensable for DNA repair and mouse development.

34 **Keywords:** NHEJ; double-strand breaks; mouse model; lymphocyte; neurodevelopment

35

### 36 1. Introduction

37 Non-homologous end-joining (NHEJ) is a molecular pathway that recognizes, processes and  
38 repairs DNA double-strand breaks (DSBs) throughout the cell cycle [1]. Core NHEJ factors Ku70 and  
39 Ku80 form heterodimer (Ku) that is rapidly associated with the DSB sites facilitating recruitment of  
40 downstream factors, including core X-ray cross-complementing 4 (XRCC4) and DNA ligase 4 (Lig4).  
41 XRCC4-like factor (XLF) is also a core factor that binds XRCC4 and stimulates Lig4-dependent DNA  
42 ligation. A number of accessory NHEJ factors are required for specific DNA end processing and DNA  
43 complex stabilization, i.e. DNA-dependent protein kinase, catalytic subunit (DNA-PKcs), nuclease  
44 Artemis, and structural components, a paralogue of XRCC4 and XLF (PAXX) and modulator of  
45 retroviral infection (Mri) [2, 3]. Mice lacking Ku70, Ku80, DNA-PKcs or Artemis possess severe  
46 combined immunodeficient phenotype (SCID), while inactivation of both alleles of *Xlf* gene results

47 in 2-3 folds reduced B and T cell count [4-8]. Mice lacking PAXX or Mri possess no or very modest  
48 phenotype due to functional redundancy with XLF [9-13]. Contrary, mice lacking either XRCC4 or  
49 Lig4 demonstrate p53- and Ku-dependent embryonic lethality, which correlates with massive  
50 neuronal apoptosis in central nervous system [1, 14-18].

51 Combined inactivation of *Xlf* and *Dna-pkcs* results in p53- and Ku70-dependent perinatal  
52 lethality in mice [11, 19, 20]. Moreover, deficiency or haploinsufficiency for *Trp53* rescues synthetic  
53 lethality between *Xlf* and *Paxx* [11]. XLF is also functionally redundant in mouse development with  
54 Mri [21], recombination activating gene 2, RAG2 [22], and a number of DNA damage response (DDR)  
55 factors, including Ataxia telangiectasia mutated (ATM) [7], histone H2AX [7, 23], Mediator of DNA  
56 damage checkpoint protein 1 (MDC1) [11], and p53-binding factor (53BP1) [8, 24].

57 Development of B and T lymphocytes depends on programmed DSBs induced by RAG during  
58 the V(D)J recombination, and NHEJ pathway, which is used for error-prone DNA repair [4].  
59 Moreover, mature B cells replace constant regions of immunoglobulins during the somatic  
60 recombination process known as class switch recombination (CSR), when DSBs are initiated by  
61 activation-induced cytidine deaminase (AID) and Uridine-N-glycosylase (UNG), and NHEJ is used  
62 for DNA repair [1, 25, 26]. Furthermore, the NHEJ process is required for neurodevelopment by  
63 preventing neuronal apoptosis [1, 27].

64 *Mri* was initially described as an *open reading frame at human chromosome 7 (C7orf49)*, a factor  
65 reversing the resistance to retroviral infection in cell lines [28]. Mri was found to enhance NHEJ [29]  
66 and possess an N-terminal Ku-binding motif (KBM) [30]. Later, Mri/Cyren was suggested to inhibit  
67 NHEJ at telomeres during the S and G2 phases of the cell cycle [31], and finally confirmed to be a *bona*  
68 *fide* NHEJ factor, which is functionally redundant with XLF in mouse development, including the  
69 V(D)J recombination and development of central nervous system [21]. However, it was not clear  
70 whether XLF and Mri functionally overlap during the early stages of neurodevelopment, e.g.  
71 supporting proliferation and self-renewal of neuronal stem cells. Moreover, due to the lack of viable  
72 mouse model deficient for both XLF and Mri, impact of Mri on B and T lymphocyte development *in*  
73 *vivo* is not fully understood.

74 Here, we introduced a frame-shift mutation to *exon 2* of the murine *Mri* gene. By interbreeding  
75 heterozygous parents, we obtained *Mri*<sup>-/-</sup>, *Mri*<sup>+/-</sup> and *Mri*<sup>+/+</sup> mice at nearly expected ratios. Mri-deficient  
76 mice possessed normal body size and number of B and T lymphocytes; however, we detected that  
77 stimulated primary mature *Mri*<sup>-/-</sup> B cells had reduced levels of IgG1, and *Mri*<sup>-/-</sup> neurospheres showed  
78 reduced proliferation rate when compared to *Mri*<sup>+/+</sup> controls.

## 79 2. Materials and Methods

### 80 2.1. Mouse models

81 All experiments involving mice were performed according to the protocols approved by the  
82 Animal Resources Care Facility of Norwegian University of Science and Technology (NTNU,  
83 Norway). *Ung*<sup>-/-</sup> mice were described previously [32]. *Mri*<sup>+/-</sup> mice were generated on request and  
84 described here for the first time.

### 85 2.2. Generation of *Mri*<sup>+/-</sup> mice

86 MRI-deficient (*Mri*<sup>-/-</sup>) mice were generated through a CRISPR/Cas9 gene-editing approach in  
87 2017 by Horizon Discovery (Saint Louis, USA) upon request from the Oksenysh group (IKOM,  
88 Faculty of Medicine and Health Science, NTNU, Norway). Single-guide RNA (sgRNA)  
89 GGG CTG TCA TCC AAG AGG GGA GG was designed to target *exon 2* of *Mri* gene in C57BL/6 mice.  
90 The 14 bp deletion resulted in a premature stop codon (Figure 1A). Cas9 and sgRNAs were injected  
91 into single-cell fertilized embryos, which were then transferred back into pseudopregnant females  
92 for gestation. Live-born pups were screened for indel mutation by DNA sequencing. Homozygous  
93 pups were used for back-crossing with wild type C57BL/6 mice. Heterozygous *Mri*<sup>+/-</sup> mice were  
94 obtained from Horizon Discovery.

### 95 2.3. Mouse genotyping

96 Two polymerase chain reactions (PCRs) were designed to determine mouse genotypes. The first  
97 PCR was performed using TCAGGTCTGCCCTACTACTGA and GTGGTGGTGCTTCTCTGTGA  
98 primers, detecting both wild type (428 bp) and null (414 bp) alleles (Figure 1B). The second PCR  
99 performed with TCAGGTCTGCCCTACTACTGA and AGAGGGGAGGACCC primers was used to  
100 validate the presence of the WT allele (234 bp, Figure 1B). The PCRs were performed using 50 ng of  
101 genomic DNA extracted from murine tissues (e.g., ears, tails), in a final reaction volume of 25  $\mu$ L,  
102 using the Taq 2x Master Mix Kit (New England Biolabs® Inc., Ipswich, Massachusetts, USA;  
103 #M0270L). The 2.5% agarose gel was used to separate 428 bp and 414 bp PCR products during 18 h  
104 at 4°C, 90 V; 0.7% agarose gel was used to detect 234 bp PCR product (75 min, room temperature,  
105 124 V). Genomic DNA isolated from *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup> cells, as well as samples with no genomic DNA,  
106 were used as PCR controls (Figure 1B).

### 107 2.4. Fluorescence-activated cell sorting, splenocyte and thymocyte count

108 Fluorescence-activated cell sorting (FACS) analysis was performed as previously described [12,  
109 33]. Briefly, spleens and thymi were isolated from 2-month-old mice, splenocytes and thymocytes  
110 were counted using Countess™ Automated Cell Counter (Invitrogen); the cell suspension was spun  
111 down and diluted with PBS to get a final cell concentration of 2.5 x 10<sup>7</sup>/mL. The samples of 2.5 x 10<sup>6</sup>  
112 splenocytes or thymocytes were blocked for 15 minutes at room temperature with Mouse BD  
113 fragment crystallizable (Fc) Block™ (1:50 dilution) (BD Biosciences, Franklin Lakes, New Jersey, USA;  
114 #553142). The cells were then incubated with fluorochrome-conjugated antibodies (see below) and  
115 sorted.

### 116 2.5. Class switch recombination

117 Class switch recombination (CSR) from IgM to IgG1 was performed as previously described [12].  
118 Naïve B lymphocytes were purified from spleens of 2-month-old mice, using EasySep mouse B cell  
119 enrichment kit (STEMCELL Technology, Vancouver, Canada; #19854) according to the  
120 manufacturers' instructions. For each CSR assay, 2 x 10<sup>4</sup> cells/200  $\mu$ L were used in duplicates. The  
121 cells were stimulated with LPS (Lipopolysaccharides, 40  $\mu$ g/ml; Sigma Aldrich, St. Louis, MO, USA;  
122 #437627-5MG) and IL-4 (Interleukin 4, 20 ng/ml; PeproTech, Stockholm, Sweden; #214-14) for 96 h.  
123 Then the cells were blocked with Fc receptor antibody (2.4G2) and normal mouse serum (Invitrogen,  
124 Carlsbad, California, USA; #10410). The cells were washed in PermWash™ (BD Biosciences, New  
125 Jersey, USA; #554723). Intracellular staining was done using fluorescently tagged anti-mouse  
126 antibodies (IgG1-APC) (BioLegend, San Diego, USA; #406610) and the succeeding wash was  
127 performed in PermWash. The cells were resuspended in 300  $\mu$ L of CellFix (BD Biosciences, New Jersey,  
128 USA; #340181). Viable CD19<sup>+</sup> B lymphocytes were analyzed for IgG1 expression using FlowJo®  
129 (Ashland, Oregon, USA) version 7.6 for Windows.

### 130 2.6. Double strand break sensitivity assay

131 DSBs sensitivity assay was performed as previously described [11, 33, 34]. Human nearly-  
132 haploid HAP1 cells were generated by Horizon Discovery Group (Waterbeach, UK,  
133 #HZGHC005061c001 and #HZGHC005061c004) and are commercially available. HAP1 cells were  
134 cultured according to the manufacturer's instructions. Doxorubicin (Selleckchem, Houston, TX, USA;  
135 #S1208), bleomycin (Selleckchem; #S1214) and etoposide (Sigma-Aldrich, USA; #E1383) were used to  
136 induce DSBs, and PrestoBlue™ Cell Viability Reagent (Thermo Fisher, USA; #A13262) was used to  
137 estimate cellular metabolism levels. Briefly, 2000 cells per well were seeded into 96-well plates, in  
138 100  $\mu$ L of IMDM medium (day 0). On day 1, 50  $\mu$ L of the medium was replaced with 50  $\mu$ L of fresh  
139 medium containing doxorubicin, bleomycin or etoposide, when indicated. Each experimental  
140 condition was performed in triplicates. On day 4, 11  $\mu$ L of 10x PrestoBlue reagent was added to the  
141 wells and incubated for 30 min at 37°C. The cellular viability was estimated according to  
142 manufacturer's instructions, using the excitation/emission wavelengths set at 544/590 nm.

### 143 2.7. Brain isolation and neural stem progenitor cell culture

144 The brain was isolated from postnatal day one mouse after the cerebellum was removed. The  
145 isolated brain was mechanically disrupted in proliferation medium consisting of Dulbecco Modified  
146 Eagle Medium, Nutrient Mixture F12 (DMEM/F12; Thermo Fisher, USA; #11330-057), supplemented  
147 with penicillin/streptomycin (Thermo Fisher, USA; #15140122), B27 without vitamin A (Thermo  
148 Fischer Scientific, USA; #12587001), EGF (10 ng/ml; PeproTech, Stockholm, Sweden; #AF-100-15) and  
149 bFGF (20ng/ml; PeproTech; #100-18B). Neural stem progenitor cells (NSPC) form free-floating  
150 globular structures referred to as neurospheres. The neurospheres were formed during the  
151 incubation at 37°C, 5% CO<sub>2</sub> and 95% humidity in order to perform proliferation and self-renewal  
152 assay (Figure 3A) [35].

### 153 2.8. Neural stem progenitor cell proliferation and self-renewal assays

154 Early passage NSPCs (P3–P10) were used throughout all the NSPC experiments. A PrestoBlue™  
155 Cell Viability Assay was used to investigate the neurosphere proliferation rates, following the  
156 manufacturer's instructions during each incubation day 1 to 7. The capacity of neural stem cells to  
157 maintain their multipotency *ex vivo* was assessed by determining the number and two-dimensional  
158 size of neurospheres [35]. Single NSPCs were plated onto 6-well suspension plates in the proliferation  
159 medium on day 0. During days 8 and 10 in culture, images of the entire wells were captured using  
160 EVOS microscope. Only areas between 50 and 1500 pixels were included in the analyses.


### 161 2.9. Antibodies

162 The following antibodies were used for FACS. Rat anti-mouse anti-CD16/CD32 (Fc Block,  
163 BD Biosciences, USA; #553141, 1 : 50); anti-CD4-PE-Cy7 (Thermo Scientific, USA, #25-0042-81, 1 : 100);  
164 anti-CD8-PE-Cy5 (BD Biosciences, USA, #553034, 1 : 100); anti-CD19-PE-Cy7 (Biolegends, USA,  
165 #115520, 1 : 100). Hamster anti-mouse anti-CD3-APC (Biolegends, USA, #100312, 1 : 100).

## 166 3. Results

### 167 3.1. Generation of *Mri*<sup>-/-</sup> mice

168 To investigate the impact of *Mri* on mouse development, we generated a mouse model with  
169 14 bp frame-shift deletion in *Mri* exon 2 on a C57BL/6 background (Figure 1A). Purified sgRNA and  
170 Cas9 RNA were introduced to fertilized oocytes, resulting in complete inactivation of the *Mri* gene.  
171 *Mri* status (WT, wild type, +/+; heterozygous, +/-; and null, -/-) was confirmed for every experiment  
172 by PCR screening (Figure 1B). *Mri*<sup>+/+</sup>, *Mri*<sup>+/-</sup> and *Mri*<sup>-/-</sup> mice were born from *Mri*<sup>+/-</sup> parents at ratios close  
173 to 1: 2: 1 (Figure 1C). Thirty-day old *Mri*<sup>-/-</sup> mice possessed an average body weight of 15.0 g, which  
174 was slightly lower but not significantly different from *Mri*<sup>+/+</sup> controls, with a bodyweight of 17.5 g, on  
175 average (Figure 1D). The lifespan of *Mri*<sup>-/-</sup> and *Mri*<sup>+/-</sup> mice was monitored for up to 12 months,  
176 according to the local regulations. During this time frame, both *Mri*<sup>-/-</sup> and *Mri*<sup>+/-</sup> mice were fertile and  
177 had no cancer incidence, similarly to the *Mri*<sup>+/+</sup> controls.



178

179

180

181

182

183

184

185

186

**Figure 1.** Generation of *Mri*<sup>-/-</sup> mice. **(A)** Top. Schematic diagram of murine *Mri* locus indicating the frame-shift mutation in the *exon 2*, induced by the sgRNA and resulting in a 14 bp deletion. Bottom. Resulting *Mri*<sup>-/-</sup> locus lacking part of the *exon 2*. **(B)** Top. PCR-based genotyping strategy reveals the *Mri* WT allele (428 bp) and *Mri* null allele (414 bp). Bottom. WT gene validation PCR reveals the *Mri* wild type allele (234 bp). **(C)** Analyses of 140 pups born from *Mri*<sup>+/-</sup> parents reveals expected genetic distribution of *Mri*<sup>+/+</sup> (29), *Mri*<sup>+/-</sup> (75) and *Mri*<sup>-/-</sup> (36) mice, which is close to the Mendelian distribution 1: 2: 1. **(D)** Body weight of six to eight week old *Mri*<sup>+/+</sup> mice (n=6) is not distinguishable from *Mri*<sup>-/-</sup> mice (n=7), p=0.4242. **(E)** The weight of spleens isolated from *Mri*<sup>+/+</sup> (n=8) and *Mri*<sup>-/-</sup> mice (n=11) is not


187 significantly different,  $p=0.8551$ . Spleen size in immunodeficient *Dna-pkcs*<sup>-/-</sup> mice (n=10) is reduced  
188 when compared to the *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup> mice,  $p<0.0001$ . (F) Splenocyte count is not affected in the *Mri*  
189 <sup>-/-</sup> mice (n=11) when compared to the *Mri*<sup>+/+</sup> (n=10),  $p=0.7713$ . A number of splenocytes in  
190 immunodeficient *Dna-pkcs*<sup>-/-</sup> mice (n=6) is significantly reduced when compared to *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup>  
191 mice,  $p<0.0001$ . (G) The weight of thymus from *Mri*<sup>+/+</sup> (n=11) and *Mri*<sup>-/-</sup> (n=11) mice is similar,  $p=0.6796$ .  
192 Thymus size in immunodeficient *Dna-pkcs*<sup>-/-</sup> mice (n=7) is significantly reduced when compared to  
193 *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup> mice,  $p<0.0001$ . (H) Thymocyte count is nearly identical in *Mri*<sup>+/+</sup> (n=8) and *Mri*<sup>-/-</sup> (n=6)  
194 mice,  $p=0.5285$ . A number of thymocytes in immunodeficient *Dna-pkcs*<sup>-/-</sup> mice (n=6) is significantly  
195 reduced when compared to *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup> mice,  $p<0.0001$ .

### 196 3.2. *Mri*<sup>-/-</sup> mice develop normal spleens and thymi

197 The NHEJ is required for the V(D)J recombination in developing B and T lymphocytes, and for  
198 CSR in mature B cells [1]. To determine specific functions of *Mri* in B and T cell development, we first  
199 analyzed spleens and thymi isolated from *Mri*-deficient and WT mice. The average weights of spleens  
200 (91 mg) and thymi (69 mg), as well as average count of splenocytes (121 million) and thymocytes  
201 (173 million), was not affected in *Mri*<sup>-/-</sup> mice when compared to *Mri*<sup>+/+</sup> controls (90 mg; 71 mg; 118  
202 million; 186 million, respectively). These numbers were significantly different from immunodeficient  
203 controls, *Dna-pkcs*<sup>-/-</sup> mice (23 mg; 10 mg; 6 million; 5 million, respectively) (Figure 1E-H). Moreover,  
204 proportions of CD19<sup>+</sup> B cells in spleens of six to eight weeks old *Mri*<sup>-/-</sup> mice were on average 60%,  
205 which was similar to the proportion of CD19<sup>+</sup> in *Mri*<sup>+/+</sup> mice (55%,  $p=0.0668$ ), and significantly higher  
206 than background levels detected in immunodeficient *Dna-pkcs*<sup>-/-</sup> controls ( $p<0.0001$ ; Figure 2A). The  
207 average proportion of CD3<sup>+</sup> T splenocytes in *Mri*<sup>-/-</sup> mice (21%) was also similar to the one observed in  
208 *Mri*<sup>+/+</sup> controls (22%,  $p=0.8228$ ), and higher than in *Dna-pkcs*<sup>-/-</sup> controls (1%,  $p<0.0001$ ; Figure 2A). *Mri*<sup>+/+</sup>  
209 and *Mri*<sup>-/-</sup> mice had similar proportions of CD4<sup>+</sup> T cells ( $p=0.8876$ ) and CD8<sup>+</sup> T cells ( $p=0.7026$ ) in the  
210 spleens, while proportions of CD4<sup>+</sup> and CD8<sup>+</sup> T splenocytes in *Dna-pkcs*<sup>-/-</sup> controls were 4-5 folds  
211 reduced ( $p<0.0001$ , Figure 2B). In thymi of six- to eight-week-old *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup> mice, proportions  
212 of CD4<sup>+</sup>, CD8<sup>+</sup> and CD4<sup>+</sup>CD8<sup>+</sup> T cells was similar ( $p>0.5589$ ), while only background levels were  
213 detected in *Dna-pkcs*<sup>-/-</sup> controls ( $p<0.0001$ , Figure 2C).

### 214 3.3. CSR to IgG1 is reduced in *Mri*<sup>-/-</sup> mice.

215 To determine whether *Mri* deficiency affects CSR, we isolated B cells from the spleens of *Mri*<sup>+/+</sup>  
216 and *Mri*<sup>-/-</sup> mice and stimulated the cells with LPS and IL-4. After 96 h, we detected that average IgG1  
217 levels were 33% in *Mri*<sup>-/-</sup> mice, which was significantly lower ( $p=0.0031$ ) than in *Mri*<sup>+/+</sup> controls  
218 (average 39%; Figure 2D). B lymphocytes isolated from *Ung*<sup>-/-</sup> mice were used as negative control and  
219 possessed on average only 2% of IgG1 at the end of the experiment (96 h), which is lower than in  
220 *Mri*<sup>+/+</sup> or *Mri*<sup>-/-</sup> mice ( $p<0.0001$ ).



221

222

223

224

225

226

227

228

229

230

231

232

233


**Figure 2.** Lymphocyte development in *Mri*<sup>-/-</sup> mice. **(A)** Proportions of T (CD3<sup>+</sup>) and B (CD19<sup>+</sup>) cells in the spleens of *Mri*<sup>+/+</sup> (n=6), *Mri*<sup>-/-</sup> (n=3) and *Dna-pkcs*<sup>-/-</sup> (n=4) mice. Proportions of T and B cells are similar in *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup> mice, p>0.0667, and are only background levels in immunodeficient *Dna-pkcs*<sup>-/-</sup> mice, p<0.0001. **(B)** Proportions of CD4<sup>+</sup> and CD8<sup>+</sup> T splenocytes in *Mri*<sup>+/+</sup> (n=6), *Mri*<sup>-/-</sup> (n=3) and *Dna-pkcs*<sup>-/-</sup> (n=4) mice. *Mri*<sup>-/-</sup> mice possess similar proportions of CD4<sup>+</sup> T helper and CD8<sup>+</sup> T cytotoxic cells when compared to *Mri*<sup>+/+</sup> mice, p=0.8876 and p=0.7026, respectively. Only background levels of CD4<sup>+</sup> and CD8<sup>+</sup> T cells are present in immunodeficient *Dna-pkcs*<sup>-/-</sup> spleens, p<0,0001. **(C)** Proportions of CD4<sup>+</sup>, CD8<sup>+</sup> and CD4<sup>+</sup>CD8<sup>+</sup> thymocytes in *Mri*<sup>+/+</sup> (n=6), *Mri*<sup>-/-</sup> (n=3) and *Dna-pkcs*<sup>-/-</sup> (n=4) mice. Proportions of T cell types in *Mri*<sup>-/-</sup> mice are similar to the ones detected in *Mri*<sup>+/+</sup> mice, p>0.5589 and higher than in *Dna-pkcs*<sup>-/-</sup> mice, p<0.0001. **(D)** CSR to IgG1 in primary B splenocytes isolated from the *Mri*<sup>-/-</sup> mice (n=4) is reduced when compared to the cells from the *Mri*<sup>+/+</sup> mice (n=3), p=0.0032. CSR to IgG1 was significantly reduced in *Ung*<sup>-/-</sup> B cells (n=3) when compared to the *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup>, p<0.0001.

### 234 3.4. Lack of *Mri* results in the reduced proliferation rate of neuronal stem progenitor cells

235 Previous studies have shown that single knockout of NHEJ DNA repair genes, e.g. *Xrcc4*, *Lig4*,  
 236 *Ku70*, results in impaired nervous system development in mice [4, 14, 15]. To determine the impact of  
 237 *Mri* on the developing nervous system, we used NSPC isolated from *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup> mice at  
 238 postnatal day 1. We performed four independent experiments using two cell lines from two mice of  
 239 each genotype. The average proliferation rate of *Mri*<sup>-/-</sup> neurospheres was approximately 35% lower  
 240 than that in WT controls,  $p=0.0043$  (Figure 3B).

### 241 3.5. Normal self-renewal capacity of *Mri*-deficient neuronal stem progenitor cells

242 To analyze the capacity of NSPCs to maintain features of stem cells throughout cell divisions  
 243 and numerous propagations (self-renewal capacity), we counted the number of neurospheres formed  
 244 in cell culture. In four independent experiments, we plated 10,000 single NSPCs and cultured for 8  
 245 days. In total, we counted 5123 neurospheres that originated from *Mri*<sup>+/+</sup>, and 4608 from *Mri*<sup>-/-</sup> mice.  
 246 On average, there were 256 neurospheres in each of 20 *Mri*<sup>+/+</sup> samples analyzed, and 230 neurospheres  
 247 in each of 20 *Mri*<sup>-/-</sup> samples ( $p=0.7254$ , n.s., Figure 3C). In addition, the images of neurospheres were  
 248 collected and the surface was calculated using *ImageJ* software. Inactivation of *Mri* did not affect the  
 249 average diameter of neurospheres, which was 461 px<sup>2</sup> on average in *Mri*<sup>+/+</sup> and 427 px<sup>2</sup> in *Mri*<sup>-/-</sup>  
 250 neurospheres,  $p=0.4915$  (Figure 3D). We concluded that *Mri* is dispensable for the self-renewal  
 251 capacity of NSPC.




252

253 **Figure 3.** Characterization of neurogenesis in *Mri*<sup>-/-</sup> mice. For each experiment, four independent cell lines  
 254 isolated from two mice were used (n=8). **(A)** Neurospheres isolation diagram from *Mri*<sup>+/+</sup> and *Mri*<sup>-/-</sup> mice at  
 255 postnatal day 1. **(B)** Neurospheres proliferation isolated from the *Mri*<sup>-/-</sup> mice is reduced when compared to

256 the *Mri*<sup>+/+</sup> mice,  $p=0.0043$ . (C) Number of neurospheres formed in cell culture for 8 days. *Mri*<sup>-/-</sup> and *Mri*<sup>+/+</sup>  
 257 neurospheres possess similar self-renewal capacity,  $p=0.7254$ . (D) Neurosphere size isolated from *Mri*<sup>-/-</sup> and  
 258 *Mri*<sup>+/+</sup> mice are similar,  $p=0.4915$ . The surface of neurospheres, pxl. Areas between 50 and 1500 pixels were  
 259 included in the analyses. Four independent experiments using two cell lines of each genotype were  
 260 performed in all experiments (A-C).  $p$  values were calculated using unpaired t-test. The horizontal bars  
 261 represent the average.

### 262 3.6. Human HAP1 cells lacking *Mri* possess normal levels of sensitivity to DSBs

263 Deficiency for XRCC4, LIG4, XLF, or DNA-PKcs results in hypersensitivity to DSBs in human  
 264 HAP1 cells [11, 33, 34]. To determine the effect of *Mri* on DSB sensitivity, we obtained two  
 265 independent clones of *MRI*-deficient HAP1 cells, as well as WT and *XRCC4*-deficient controls. We  
 266 exposed the HAP1 cells to DSB-inducing agents bleomycin (0 to 0.4  $\mu$ M), doxorubicin (0 to 4 nM) and  
 267 etoposide (0 to 160 nM), and evaluated the cell viability 4 days later (Figure 4). We observed no  
 268 hypersensitivity of HAP1 cells lacking *Mri* when compared to WT controls. However, cells lacking  
 269 *XRCC4* were hypersensitive to all indicated compounds, bleomycin, doxorubicin, and etoposide  
 270 ( $p<0.0001$ , Figure 4).



271

272 **Figure 4.** Sensitivity to DSBs in *Mri*-deficient HAP1 cells. Sensitization of WT, two independent *Mri*-  
 273 deficient clones, *MRI*<sup>Δ1</sup> and *MRI*<sup>Δ2</sup>, and *XRCC4*<sup>Δ</sup> HAP1 cells to bleomycin (A), doxorubicin (B), and  
 274 etoposide (C) at indicated concentrations. Results are from the mean (SD) of three repeats. Cell viability (%)  
 275 represents the relative proportion of the fluorescence normalized to untreated cells. Comparisons between  
 276 every two groups were made using one-way ANOVA, GraphPad Prism 8. WT, *MRI*<sup>Δ1</sup> and *MRI*<sup>Δ2</sup> vs *XRCC4*<sup>Δ</sup>,  
 277  $p<0.0001$  (\*\*\*\*); WT vs *MRI*<sup>Δ1</sup>,  $p=0.9983$  (n.s); WT vs *MRI*<sup>Δ2</sup>,  $p=0.1295$  (n.s); *MRI*<sup>Δ1</sup> vs *MRI*<sup>Δ2</sup>,  $p=0.1791$  (n.s).

## 278 4. Discussion

279 We have generated a new knockout mouse model with 14 bp deletion in *exon 2* of the *Mri* gene,  
 280 *Mri*<sup>-/-</sup>. While we were characterizing our mouse model, another group reported an independently-  
 281 generated *Mri*-deficient mouse [21], which possessed a similar phenotype. Thus, our observations are  
 282 confirmatory to the findings observed by the Sleckman group [21].

283 The mice lacking *Mri* are live-born at expected ratios and demonstrate normal growth and  
 284 development of lymphoid organs. *Mri*<sup>-/-</sup>, *Mri*<sup>+/-</sup> and *Mri*<sup>+/+</sup> mice possess similar sizes of spleens and  
 285 thymi, a similar number of splenocytes and thymocytes, and proportions of B and T cells (Figure 1).  
 286 Similarly to *Mri*-deficient mice, *Paxx*<sup>-/-</sup> mice did not have detectable phenotype [9-13]. However,  
 287 inactivation of other NHEJ factors resulted in reduced number of B and T cells (*Xlf*<sup>-/-</sup> mice, [5-8, 19, 22,  
 288 24]), block in B and T cell development, e.g. *Artemis*<sup>-/-</sup> [36], *Dna-pkcs*<sup>-/-</sup> [37], *Ku70*<sup>-/-</sup> [38], *Ku80*<sup>-/-</sup> [39]; or  
 289 even embryonic lethality in *Xrcc4*<sup>-/-</sup> [40] and *Lig4*<sup>-/-</sup> [41].

290 The CSR to IgG1 was reduced in primary B cells isolated from *Mri*<sup>-/-</sup> mice when compared to WT  
 291 controls (Figure 2), which suggests that *Mri* is involved in specific DNA repair-mediated event.  
 292 Furthermore, we isolated neuronal stem progenitor cells from *Mri*<sup>-/-</sup> brains and found that these cells  
 293 proliferate slower when compared to *Mri*<sup>+/+</sup> controls. Reduced proliferation rates of *Mri*-deficient  
 294 neuronal stem progenitor cells could be explained, as one option, by lower expression or lack of  
 295 factors functionally redundant with *Mri* in these cell types. Future studies would be required to  
 296 address this option. Moreover, future studies may address questions such as neurological defects and

297 cognitive functions in mice lacking *Mri*, as well as whether the *Mri*-deficient mice are prone to  
298 infections.

299 In addition, we found that human nearly haploid HAP1 cell lines lacking *Mri* possessed no  
300 proliferation defect or hypersensitivity to DNA damaging agents, such as etoposide, doxorubicin and  
301 bleomycin (Figure 4). Previously, it was reported that murine embryonic fibroblasts (MEF) lacking  
302 *Mri* are hypersensitive to ionizing radiation when compared to WT controls, although the sensitivity  
303 is less obvious than in XLF-deficient MEFs [21]. The discrepancy between our and previously  
304 published data could be due to the usage of different cell types, difference between species, as well  
305 as distinct ways to induce DNA damages (e.g., chemicals vs irradiation). Further studies involving  
306 various cell type models originated from different species, and using various DNA damaging  
307 strategies, would deepen our understanding of the specific functions of *Mri* in DNA repair in  
308 mammalian cells. Overall, we concluded that the lack of *Mri* has rather a minor effect on murine and  
309 human cells.

310 Combined inactivation of *Mri* and *Xlf* [21], however, revealed an important role of *Mri* in mouse  
311 development, which was overlooked due to its functional redundancy with XLF. Synthetic lethality  
312 between *Mri* and *Xlf* complicated studies of genetic interaction between these factors *in vivo*. There  
313 are several potential ways to overcome this challenge. One option is to use conditional knockouts of  
314 *Xlf* or *Mri* genes. Moreover, there might be another genetic-based approach. Inactivation of one or  
315 two alleles of *Trp53* partially rescued synthetic lethality between *Xlf* and *Dna-pkcs* [11, 19, 20] and *Xlf*  
316 and *Paxx* [11]. In addition, deficiency or haploinsufficiency for *Trp53* rescued embryonic lethality of  
317 *Lig4*<sup>-/-</sup> and *Xrcc4*<sup>-/-</sup> mice [14, 15]. Inactivation of the *Atm* gene rescued embryonic lethality of *Lig4*<sup>-/-</sup> mice  
318 [42]. Finally, inactivation of both alleles of *Ku80* rescued embryonic lethality of *Lig4*<sup>-/-</sup> mice [18], and  
319 inactivation of *Ku70* rescued synthetic lethality between *Xlf* and *Dna-pkcs* [20]. Based on these data,  
320 one can speculate that inactivation of *Trp53*, *Atm*, *Ku70* or *Ku80* will rescue synthetic lethality between  
321 *Xlf* and *Mri*. Moreover, given critical roles of *Ku70* and *Ku80* in initiation of classical NHEJ, one could  
322 propose that mice lacking all known NHEJ factors, e.g. *Ku70*<sup>-/-</sup>*Ku80*<sup>-/-</sup>*Dna-pkcs*<sup>-/-</sup>*Artemis*<sup>-/-</sup>*Xlf*<sup>-/-</sup>*Paxx*<sup>-/-</sup>*Mri*  
323 <sup>-/-</sup>*Xrcc4*<sup>-/-</sup>*Lig4*<sup>-/-</sup> will be viable, indistinguishable from *Ku*-deficient mice, and serve as a suitable *in vivo*  
324 model to investigate alternative end-joining, A-EJ.

## 325 5. Conclusions

326 A new *Mri*-deficient mouse model was generated. *Mri*-deficient mice possessed normal body  
327 size and number of B and T lymphocytes; however, *Mri* is required for efficient class switch  
328 recombination process in mature B cells. *Mri*<sup>-/-</sup> neurospheres showed reduced proliferation rate, but  
329 similar self-renewal capacity, when compared to *Mri*<sup>+/+</sup> controls.

330 **Author Contributions:** V.O. designed and performed experiments, contributed key reagents and analyzed the  
331 data. A.S. performed CSR assay using primary B cells. MT.X. performed DSBs sensitivity assay using human  
332 HAP1 cells. S.C.Z., C.H., Ø.R., Q.Z., A.L., J.W., NB.L. performed lymphocyte analyzes. Ø.R., W.W., and P.J.  
333 performed and analyzed neurosphere-based experiments. R.GF developed *Mri*<sup>-/-</sup> genotyping strategy. M.B. and  
334 V.O. interpreted the results. The paper was written by Ø.R., S.C.Z. and V.O.; all the authors read and approved  
335 the manuscript.

336 **Funding:** This work was supported by the Research Council of Norway Young Talent Investigator grant (#  
337 249774) to VO. In addition, VO group was supported by the Liaison Committee for education, research and  
338 innovation in Central Norway (# 13477), the Norwegian Cancer Society (# 182355), FRIMEDBIO grants (# 270491  
339 and # 291217), and The Outstanding Academic Fellow Program at NTNU (2017-2021). JW is supported by  
340 Erasmus mobility program.

341 **Acknowledgments:** We gratefully acknowledge support by Molecular Imaging Core Facility (CMIC) and  
342 Comparative Medicine Core Facility (CoMed) at the Faculty of Medicine and Health Sciences, NTNU  
343 (Trondheim).

344 **Conflicts of Interest:** The authors declare no conflict of interest.

345 **Abbreviations:**

346	ATM	Ataxia-telangiectasia mutated
347	CSR	Class switch recombination
348	DDR	DNA damage response
349	DNA-PKcs	DNA-dependent protein kinase
350	DSBs	DNA double-strand breaks
351	GFAP	Glial fibrillary acid protein
352	HAP1	A near-haploid human cell line derived from KBM-7 cell line
353	IL-4	Interleukin 4
354	Lig4	DNA ligase IV
355	LPS	Lipopolysaccharides
356	Mri	Modulator of retroviral infection
357	NHEJ	Non-homologous end-joining
358	NSPC	Neuronal stem progenitor cells
359	PAXX	Paralogue of XRCC4 and XLF
360	PCR	Polymerase chain reaction
361	XLF	XRCC4-like factor
362	XRCC4	X-ray repair cross-complementing protein 4

### 363 References

- 364 1. Kumar, V., F.W. Alt, and V. Oksenychn, *Functional overlaps between XLF and the ATM-dependent DNA*  
365 *double strand break response*. DNA Repair (Amst), 2014. **16**: p. 11-22. DOI: 10.1016/j.dnarep.2014.01.010
- 366 2. Pannunzio, N.R., G. Watanabe, and M.R. Lieber, *Nonhomologous DNA end-joining for repair of DNA*  
367 *double-strand breaks*. J Biol Chem, 2018. **293**(27): p. 10512-10523. DOI: 10.1074/jbc.TM117.000374
- 368 3. Scully, R., et al., *DNA double-strand break repair-pathway choice in somatic mammalian cells*. Nat Rev Mol  
369 Cell Biol, 2019. DOI: 10.1038/s41580-019-0152-0
- 370 4. Kumar, V., F.W. Alt, and V. Oksenychn, *Reprint of "Functional overlaps between XLF and the ATM-dependent*  
371 *DNA double strand break response"*. DNA Repair (Amst), 2014. **17**: p. 52-63. DOI:  
372 10.1016/j.dnarep.2014.04.004
- 373 5. Li, G., et al., *Lymphocyte-specific compensation for XLF/cernunnos end-joining functions in V(D)J*  
374 *recombination*. Mol Cell, 2008. **31**(5): p. 631-40. DOI: 10.1016/j.molcel.2008.07.017
- 375 6. Vera, G., et al., *Cernunnos deficiency reduces thymocyte life span and alters the T cell repertoire in mice and*  
376 *humans*. Mol Cell Biol, 2013. **33**(4): p. 701-11. DOI: 10.1128/MCB.01057-12
- 377 7. Zha, S., et al., *ATM damage response and XLF repair factor are functionally redundant in joining DNA breaks*.  
378 Nature, 2011. **469**(7329): p. 250-4. DOI: 10.1038/nature09604
- 379 8. Oksenychn, V., et al., *Functional redundancy between repair factor XLF and damage response mediator 53BP1*  
380 *in V(D)J recombination and DNA repair*. Proc Natl Acad Sci U S A, 2012. **109**(7): p. 2455-60. DOI:  
381 10.1073/pnas.1121458109
- 382 9. Abramowski, V., et al., *PAXX and Xlf interplay revealed by impaired CNS development and immunodeficiency*  
383 *of double KO mice*. Cell Death Differ, 2018. **25**(2): p. 444-452. DOI: 10.1038/cdd.2017.184
- 384 10. Balmus, G., et al., *Synthetic lethality between PAXX and XLF in mammalian development*. Genes Dev, 2016.  
385 **30**(19): p. 2152-2157. DOI: 10.1101/gad.290510.116
- 386 11. Castaneda-Zegarra, S., et al., *Synthetic lethality between DNA repair factors Xlf and Paxx is rescued by*  
387 *inactivation of Trp53*. DNA Repair (Amst), 2019. **73**: p. 164-169. DOI: 10.1016/j.dnarep.2018.12.002
- 388 12. Gago-Fuentes, R., et al., *Normal development of mice lacking PAXX, the paralogue of XRCC4 and XLF*. FEBS  
389 Open Bio, 2018. **8**(3): p. 426-434. DOI: 10.1002/2211-5463.12381
- 390 13. Liu, X., et al., *PAXX promotes KU accumulation at DNA breaks and is essential for end-joining in XLF-deficient*  
391 *mice*. Nat Commun, 2017. **8**: p. 13816. DOI: 10.1038/ncomms13816

- 392 14. Frank, K.M., et al., *DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via*  
393 *the p53 pathway*. *Mol Cell*, 2000. **5**(6): p. 993-1002.
- 394 15. Gao, Y., et al., *Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and*  
395 *development*. *Nature*, 2000. **404**(6780): p. 897-900. DOI: 10.1038/35009138
- 396 16. Boboila, C., et al., *Alternative end-joining catalyzes robust IgH locus deletions and translocations in the*  
397 *combined absence of ligase 4 and Ku70*. *Proc Natl Acad Sci U S A*, 2010. **107**(7): p. 3034-9. DOI:  
398 10.1073/pnas.0915067107
- 399 17. Boboila, C., et al., *Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and*  
400 *DNA ligase 4*. *J Exp Med*, 2010. **207**(2): p. 417-27. DOI: 10.1084/jem.20092449
- 401 18. Karanjawala, Z.E., et al., *The embryonic lethality in DNA ligase IV-deficient mice is rescued by deletion of Ku:*  
402 *implications for unifying the heterogeneous phenotypes of NHEJ mutants*. *DNA Repair (Amst)*, 2002. **1**(12): p.  
403 1017-26.
- 404 19. Oksenyck, V., et al., *Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J*  
405 *recombination and nonhomologous DNA end joining*. *Proc Natl Acad Sci U S A*, 2013. **110**(6): p. 2234-9. DOI:  
406 10.1073/pnas.1222573110
- 407 20. Xing, M., et al., *Synthetic lethality between murine DNA repair factors XLF and DNA-PKcs is rescued by*  
408 *inactivation of Ku70*. *DNA Repair (Amst)*, 2017. **57**: p. 133-138. DOI: 10.1016/j.dnarep.2017.07.008
- 409 21. Hung, P.J., et al., *MRI Is a DNA Damage Response Adaptor during Classical Non-homologous End Joining*.  
410 *Mol Cell*, 2018. **71**(2): p. 332-342 e8. DOI: 10.1016/j.molcel.2018.06.018
- 411 22. Lescale, C., et al., *RAG2 and XLF/Cernunnos interplay reveals a novel role for the RAG complex in DNA repair*.  
412 *Nat Commun*, 2016. **7**: p. 10529. DOI: 10.1038/ncomms10529
- 413 23. Chen, B.R., et al., *XLF and H2AX function in series to promote replication fork stability*. *J Cell Biol*, 2019.  
414 **218**(7): p. 2113-2123. DOI: 10.1083/jcb.201808134
- 415 24. Liu, X., et al., *Overlapping functions between XLF repair protein and 53BP1 DNA damage response factor in*  
416 *end joining and lymphocyte development*. *Proc Natl Acad Sci U S A*, 2012. **109**(10): p. 3903-8. DOI:  
417 10.1073/pnas.1120160109
- 418 25. Alt, F.W., et al., *Mechanisms of programmed DNA lesions and genomic instability in the immune system*. *Cell*,  
419 2013. **152**(3): p. 417-29. DOI: 10.1016/j.cell.2013.01.007
- 420 26. Yeap, L.S. and F.L. Meng, *Cis- and trans-factors affecting AID targeting and mutagenic outcomes in antibody*  
421 *diversification*. *Adv Immunol*, 2019. **141**: p. 51-103. DOI: 10.1016/bs.ai.2019.01.002
- 422 27. Alt, F.W. and B. Schwer, *DNA double-strand breaks as drivers of neural genomic change, function, and disease*.  
423 *DNA Repair (Amst)*, 2018. **71**: p. 158-163. DOI: 10.1016/j.dnarep.2018.08.019
- 424 28. Agarwal, S., et al., *Isolation, characterization, and genetic complementation of a cellular mutant resistant to*  
425 *retroviral infection*. *Proc Natl Acad Sci U S A*, 2006. **103**(43): p. 15933-8. DOI: 10.1073/pnas.0602674103
- 426 29. Slavoff, S.A., et al., *A human short open reading frame (sORF)-encoded polypeptide that stimulates DNA end*  
427 *joining*. *J Biol Chem*, 2014. **289**(16): p. 10950-7. DOI: 10.1074/jbc.C113.533968
- 428 30. Grundy, G.J., et al., *The Ku-binding motif is a conserved module for recruitment and stimulation of non-*  
429 *homologous end-joining proteins*. *Nat Commun*, 2016. **7**: p. 11242. DOI: 10.1038/ncomms11242
- 430 31. Arnoult, N., et al., *Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN*.  
431 *Nature*, 2017. **549**(7673): p. 548-552. DOI: 10.1038/nature24023
- 432 32. Nilsen, H., et al., *Uracil-DNA glycosylase (UNG)-deficient mice reveal a primary role of the enzyme during*  
433 *DNA replication*. *Mol Cell*, 2000. **5**(6): p. 1059-65.

- 434 33. Dewan, A., et al., *Robust DNA repair in PAXX-deficient mammalian cells*. *FEBS Open Bio*, 2018. **8**(3): p. 442-448. DOI: 10.1002/2211-5463.12380
- 435
- 436 34. Xing, M. and V. Oksenyck, *Genetic interaction between DNA repair factors PAXX, XLF, XRCC4 and DNA-*
- 437 *PKcs in human cells*. *FEBS Open Bio*, 2019. DOI: 10.1002/2211-5463.12681
- 438 35. Wang, W., et al., *Mitochondrial DNA integrity is essential for mitochondrial maturation during differentiation*
- 439 *of neural stem cells*. *Stem Cells*, 2010. **28**(12): p. 2195-204. DOI: 10.1002/stem.542
- 440 36. Rooney, S., et al., *Leaky Scid phenotype associated with defective V(D)J coding end processing in Artemis-*
- 441 *deficient mice*. *Mol Cell*, 2002. **10**(6): p. 1379-90. DOI: 10.1016/s1097-2765(02)00755-4
- 442 37. Gao, Y., et al., *A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J*
- 443 *recombination*. *Immunity*, 1998. **9**(3): p. 367-76.
- 444 38. Gu, Y., et al., *Growth retardation and leaky SCID phenotype of Ku70-deficient mice*. *Immunity*, 1997. **7**(5): p.
- 445 653-65.
- 446 39. Nussenzweig, A., et al., *Requirement for Ku80 in growth and immunoglobulin V(D)J recombination*. *Nature*,
- 447 1996. **382**(6591): p. 551-5. DOI: 10.1038/382551a0
- 448 40. Gao, Y., et al., *A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis*. *Cell*, 1998.
- 449 **95**(7): p. 891-902.
- 450 41. Frank, K.M., et al., *Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV*.
- 451 *Nature*, 1998. **396**(6707): p. 173-7. DOI: 10.1038/24172
- 452 42. Sekiguchi, J., et al., *Genetic interactions between ATM and the nonhomologous end-joining factors in genomic*
- 453 *stability and development*. *Proc Natl Acad Sci U S A*, 2001. **98**(6): p. 3243-8. DOI: 10.1073/pnas.051632098